GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (OTCPK:GLPGF) » Definitions » 14-Day RSI

Galapagos NV (Galapagos NV) 14-Day RSI : 51.61 (As of Apr. 27, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-27), Galapagos NV's 14-Day RSI is 51.61.

The industry rank for Galapagos NV's 14-Day RSI or its related term are showing as below:

GLPGF's 14-Day RSI is ranked better than
97.4% of 1575 companies
in the Biotechnology industry
Industry Median: 44.62 vs GLPGF: 51.61

Competitive Comparison of Galapagos NV's 14-Day RSI

For the Biotechnology subindustry, Galapagos NV's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Galapagos NV's 14-Day RSI falls into.



Galapagos NV  (OTCPK:GLPGF) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galapagos NV  (OTCPK:GLPGF) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Galapagos NV 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Galapagos NV's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (Galapagos NV) Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.